Abivax Crashes 44% After Miracle Drug Flags Cancer Risks — Breakthrough or Fatal Flaw?

Abivax just suffered a staggering 44% collapse in a single trading session, leaving Wall Street completely shell-shocked. The biotech firm initially spiked 20% on stellar Phase 3 trial results for its ulcerative colitis drug, obefazimod, which posted an impressive 51% efficacy rate. But the euphoria evaporated the moment investors dug into the safety data and discovered rare malignancy cases.In this episode of Implied, we unpack the brutal market reaction—from an 8x volume explosion and a massive Jefferies downgrade to looming shareholder lawsuits. Is this safety overhang a total dealbreaker for the drug, or is it just statistical noise creating a high-risk buying opportunity? Tune in to find out whether you should stay on the sidelines or brace for a massive reversal.